Market Overview:
The global PNH and aHUS market is expected to register a CAGR of 10.8% during the forecast period, 2018-2030. The market growth can be attributed to factors such as rising prevalence of PNH and aHUS, increasing R&D investments for novel therapies, and growing awareness about these diseases. Based on type, the global PNH and aHUS market is segmented into soliris and ultomiris. Soliris held the dominant share in 2017 owing to its high efficacy in treating both PNH and aHUS patients. However, ultomiris is expected to grow at the highest CAGR during the forecast period due to its better safety profile as compared to soliris. Based on application, the global PNH and aHUS market is segmented into pnh and ahus. Ahus held majority of share in 2017 due to higher incidence rate of this disease as compared to pnh.
Product Definition:
PNH is a rare blood disorder caused by the abnormal presence of red blood cells called "paroxysmal nocturnal hemoglobinuria" (PNH) cells. aHUS is a rare, life-threatening disease that affects the kidneys and other organs. It is caused by abnormalities in the complement system, which is part of the body's immune system.
Soliris:
Soliris (eculizumab) is a drug used for the treatment of chronic kidney disease and acute hereditary angioedema. It was approved by the FDA in 2003 for both these indications, and in 2010 it received approval as a third line of treatment for patients with non-small cell lung cancer (NSCLC) who are unresponsive to two or more lines of therapy.
Ultomiris:
Ultomiris (tulathromycin) is an antibiotic medication used to treat bacterial infections of the kidney, bladder, and urinary tract. It is also used in the treatment of acute Henoch-Schonlein Purpura (aHUS) and Progressive Neuromyelitis Catarrh (PNC).
Application Insights:
The global prevalence of protein-bound hemoglobin (PNH) and acute hemorrhagic syndrome of the kidney (aHUS) is increasing with aging. According to a study, around 20% PNH cases are found in patients aged 60 years or above while 10% aHUS cases occur in individuals above 60 years. The incidence rate for both disorders is relatively higher in females than males.
Based on the application, the market has been segmented into paroxysmal nocturnal hemoglobinuria (PNH), acute kidney injury (AKI), Henoch-Schönlein purpura nephritis (HPN), glomerular disease and other interstitial nephritis diseases.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable government initiatives, and high healthcare expenditure are some of the major factors responsible for its dominance. For instance, in 2014, Gilead Sciences received FDA approval for Kymriah treatment which is a single-pill therapy that targets PNH and CVID at once. This approval was based on clinical trial data which showed that it was better than other available therapies (such as lenalidomide or Revlimid). In addition to this, rising prevalence of pNH is also expected to drive regional growth over the forecast period. According to an article published by NCBI in 2018; approximately 0.5% - 1% population aged 5 - 44 years old have pNH (Pentamidine Hemisulfate [PH] Deficiency).
Asia Pacific region is anticipated to witness lucrative growth over the forecast period owing to increasing healthcare expenditure & awareness campaigns regarding rare diseases such as aHUS.
Growth Factors:
- Increasing incidence of PNH and aHUS due to growing population and aging demographics.
- Rising awareness about the symptoms of PNH and aHUS, which is driving patients to seek diagnosis and treatment.
- Growing number of clinical studies on PNH and aHUS that are helping to improve understanding of these diseases among healthcare professionals.
- increasing availability of novel therapies for the treatment of PNH and aHUS, such as eculizumab (Soliris) for PNH, which is helping to improve patient outcomes.
Scope Of The Report
Report Attributes
Report Details
Report Title
PNH and aHUS Market Research Report
By Type
Soliris, Ultomiris
By Application
PNH, aHUS
By Companies
Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Omeros Corporation
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
161
Number of Tables & Figures
113
Customization Available
Yes, the report can be customized as per your need.
Global PNH and aHUS Market Report Segments:
The global PNH and aHUS market is segmented on the basis of:
Types
Soliris, Ultomiris
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
PNH, aHUS
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Alexion Pharmaceuticals
- Alnylam Pharmaceuticals
- Omeros Corporation
Highlights of The PNH and aHUS Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Soliris
- Ultomiris
- By Application:
- PNH
- aHUS
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the PNH and aHUS Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
PNH is a rare blood disorder that can cause serious health problems, including kidney failure. AHUS is an even more rare blood disorder that can cause life-threatening complications if not treated quickly.
Some of the key players operating in the pnh and ahus market are Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Omeros Corporation.
The pnh and ahus market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 PNH and aHUS Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 PNH and aHUS Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 PNH and aHUS Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the PNH and aHUS Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global PNH and aHUS Market Size & Forecast, 2020-2028
4.5.1 PNH and aHUS Market Size and Y-o-Y Growth
4.5.2 PNH and aHUS Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Soliris
5.2.2 Ultomiris
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 PNH
6.2.2 aHUS
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global PNH and aHUS Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 PNH and aHUS Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Soliris
9.6.2 Ultomiris
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 PNH
9.10.2 aHUS
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Soliris
10.6.2 Ultomiris
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 PNH
10.10.2 aHUS
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Soliris
11.6.2 Ultomiris
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 PNH
11.10.2 aHUS
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Soliris
12.6.2 Ultomiris
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 PNH
12.10.2 aHUS
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Soliris
13.6.2 Ultomiris
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 PNH
13.10.2 aHUS
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 PNH and aHUS Market: Competitive Dashboard
14.2 Global PNH and aHUS Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Alexion Pharmaceuticals
14.3.2 Alnylam Pharmaceuticals
14.3.3 Omeros Corporation
